Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]
BMC Cancer, 2012 Background Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Mian Afsar +8 more
doaj +3 more sources
BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy [PDF]
Annals of HematologyWe report the case of a 51-year-old male patient initially diagnosed with JAK2-V617F-mutated polycythemia vera (PV), who developed chronic phase BCR::ABL1-positive chronic myeloid leukemia (CML) 11 years later.
Paride Bartolucci +7 more
doaj +2 more sources
PLoS ONE, 2022 Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between chromosomes 9 and 22 which creates an abnormal fusion gene, BCR::ABL1.
Dawne N Shelton +7 more
doaj +2 more sources
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. [PDF]
PLoS ONE, 2011 Amongst all leukemias, Bcr-Abl positive chronic myelogenous leukemia (CML) confers resistance to native drug due to multi drug resistance and also resistance to p53 and fas ligand pathways.
Abhalaxmi Singh +2 more
doaj +1 more source
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. [PDF]
PLoS ONE, 2013 Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies.
Octavian Bucur +7 more
doaj +1 more source
Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]
Vojnosanitetski Pregled, 2022 Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj +4 more
doaj +1 more source
Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) chimeric transcripts [PDF]
Precision and Future Medicine, 2019 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most ...
Jae Won Yun +5 more
doaj +1 more source
Hematology, Transfusion and Cell Therapy, 2022 Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success.
Carla Boquimpani +8 more
doaj +1 more source
Several different cytogenetic clones arising during treatment of Philadelphia positive chronic myeloid leukemia with tyrosine kinase inhibitors lead to the progression into Philadelphia negative acute myeloid leukemia [PDF]
Vojnosanitetski Pregled, 2021 Introduction. Additional karyotype abnormalities in the Philadelphia-positive (Ph+) clone can emerge during the progression of chronic myeloid leukemia (CML) and are of-ten associated with the resistance to treatment with tyrosine kinase inhibitors (TKI).
Denčić-Fekete Marija +6 more
doaj +1 more source
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1. [PDF]
PLoS ONE, 2015 Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML).
Pamela Y Ting +12 more
doaj +1 more source